Based on these results, we conclude that this is a reasonable procedure for younger adult patients with focal osteochondral talar defects that cannot be corrected with curettage and microfracture.

Background Mesenchymal stromal cells (MSCs) have been shown in rodent models to promote primary and pulmonary metastatic sarcoma growth when injected in the presence of gross tumor. In theory, this would limit their use in a clinical setting after limb salvage treatment for osteosarcoma. Although concerning, these models do not translate to the clinical setting wherein MSCs could be used after primary tumor resection to aid in bone healing and incorporation of tumor endoprostheses. If we can determine whether the use of MSCs in this setting is safe, it might improve our ability to augment bone healing in patients undergoing limb salvage. Questions/purposes The purpose of this study was to determine (1) whether MSCs promote pulmonary metastatic disease progression in a murine osteosarcoma model; and/or (2) whether they affect local disease recurrence in the presence of microscopic residual osteosarcoma. Methods An orthotopic model of luciferase-expressing osteosarcoma was developed. At 10 days, resection of the primary tumor was performed. One hundred fourteen female C3H mice were inoculated with DLM8-luc osteosarcoma in the proximal tibia. Ninety-four mice developed orthotopic osteosarcoma with luciferase expression. Mice with bioluminescent evidence of a primary tumor received either a microscopically ''clean'' amputation at a time when residual microscopic metastatic disease was present in the lungs (pulmonary metastasis group; n = 65) or a ''dirty'' amputation (local recurrence group; n = 29). Mice were randomized to receive intravenous MSCs, MSCs at the surgical site, or no MSCs. Mice were monitored for development and progression of pulmonary metastasis and local recurrence by bioluminescence imaging and daily measurements at the surgical site. The number of pulmonary nodules, time to first evidence of metastasis, and size of recurrent tumor were compared using Kruskal-Wallis, analysis of variance, Welch's, t-tests, or Mann-Whitney tests as appropriate for the specific data sets with p \ 0.05 considered significant. Results Mice receiving intravenous MSCs had a faster time to first detection of pulmonary metastasis (2.93 ± 1.90 days) compared with mice with local injection of MSCs (6.94 ± 6.78 days) or no MSCs (5.93 ± 4.55 days)

Administration of xylazine induced a dose-dependent ataxia in horses and resulted in significant changes of gait parameters, pelvic accelerations, and stabilographic variables, some of which changed in a dose-dependent fashion. Some of the altered gait parameters in this model were probably a result of overall slowing down of the stride cycle secondary to the sedative effect. Continued efforts to discover and evaluate quantifiable gait parameters that are susceptible to change following development of clinical neurological disease in horses is warranted.

Diversity is a key driver of innovation and a critical component of success on a global scale. Countries that deploy strategies to foster greater inclusion of all inventors in the innovation lifecycle will ultimately be best positioned to maximize their gross domestic product and ensure economic prosperity. The U.S is losing ground because it is not fully engaging a significant portion of the inventive talent pool. According to a 2019 report from the U.S. Patent & Trademark Office, the share of women among all U.S. inventor-patentees is only 12.8%.In an effort to understand factors that encouraged and discouraged academic women’s participation in technology commercialization, a group of Technology Transfer professionals conducted a survey of academic women involved in innovation, invention and/or entrepreneurship. The 168 respondents were from public and private research institutions of varying sizes from all regions of the United States. This paper outlines the key findings from the qualitative and quantitative data around the themes that emerged. It also puts forth a set of recommendations based on the survey feedback, follow-up interviews, and the collective experience of Technology Transfer professionals who work daily with academic innovators. It is our hope that these recommendations will provide valuable insights into concrete actions that can be taken to ensure systemic changes that foster greater engagement of academic women and other under-represented populations in all stages of the innovation lifecycle.